Bookmark and Share

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett VJ, Figueroa AL, Piscitelli P, Singleton W, Witztum JL, Geary RS, Tsimikas S, O'Dea LSL; Vupanorsen Study Investigators.
Eur Heart J. 2020;41:3936-3945

Aims: Loss-of-function mutations in ANGPTL3 are associated with beneficial effects on lipid and glucose metabolism and reduced risk of coronary artery disease. Vupanorsen (AKCEA-ANGPTL3-L Rx ) is an N-acetyl galactosamine-conjugated antisense oligonucleotide targeted to the liver that selectively inhibits angiopoietin-like 3 (ANGPTL3) protein synthesis.
Methods and results: This was a double-blind, placebo-controlled, dose-ranging, Phase 2 study. Patients (N =105) with fasting triglycerides >150 mg/dL (>1.7 mmol/L), type 2 diabetes, and hepatic steatosis were treated for 6 months with 40 or 80 mg every 4 weeks (Q4W), or 20 mg every week (QW) of vupanorsen, or placebo given subcutaneously. The primary efficacy endpoint was per cent change in fasting triglycerides from baseline at 6 months. Median baseline triglycerides were 2.84 mmol/L (252 mg/dL). Significant reductions in triglycerides of 36%, 53%, 47%, and in ANGPTL3 of 41%, 59%, 56%, were observed in the 40 mg Q4W, 80 mg Q4W, and 20 mg QW groups, respectively, compared with 16% reduction in triglycerides and 8% increase in ANGPTL3 in placebo. Compared with placebo, vupanorsen 80 mg Q4W reduced apolipoprotein C-III (58%), remnant cholesterol (38%), total cholesterol (19%), non-high-density lipoprotein cholesterol (HDL-C; 18%), HDL-C (24%), and apolipoprotein B (9%). There was no improvement in glycaemic parameters, or hepatic fat fraction. Treatment with vupanorsen was not associated with clinically significant changes in platelet counts, and the most common adverse events were those at the injection site, which were generally mild.
Conclusion: Vupanorsen results in a favourable lipid/lipoprotein profile and provides a potential strategy for residual cardiovascular risk reduction.
Keywords: Antisense; Cardiovascular disease; Hypertriglyceridaemia; Vupanorsen; Angiopoietin-like protein 3


Eur Heart J. 2020;41:3936-3945



Area Soci


34° Congresso Nazionale

34° Congresso Nazionale

Virtual edition,
22-24 Novembre 2020
Programma completo

[continua a leggere]

Congresso Regionale SISA Sezione Triveneto

Webinar, 29 Maggio 2021

[continua a leggere]

Spring Meeting Gruppi Giovani SIIA, SIMI, SIPREC, SISA 2021

Virtual Edition,
21-22 Maggio 2021

[continua a leggere]

Congresso Regionale SISA Sezione Lazio

Online Edition, 12 Dicembre 2020

[continua a leggere]

SISA LIPID ACADEMY - Corso avanzato di lipidologia clinica

Digital Edition

[continua a leggere]

Congresso Regionale SISA Sezione Lombardia

Milano, 15-17 Ottobre 2020
Programma preliminare

[continua a leggere]

Giornale Italiano Arteriosclerosi

Rivista in lingua italiana
riservata ai Soci S.I.S.A.
Ultimo numero:
Anno 11 • N.4/2020

[continua a leggere]

HoFH today

Rivista Italiana della
Familiare Omozigote
Anno 2 • N.1/2020

[continua a leggere]

Rivista NMCD

Nutrition, Metabolism and Cardiovascular Diseases

Istruzioni per l'accesso online

IF 2018: 3.340


EAS Advanced Course in Rare Lipid Disease
[continua a leggere]
Progetto vincitore della Borsa di Studio "Andrea Mezzetti" 2019 - C. Marchi
[continua a leggere]


Per essere informati sulle novità di S.I.S.A. iscrivetevi alla nostra newsletter inserendo
il vostro indirizzo di posta elettronica

Progetto LIPIGEN

Nuovo sito dedicato al Progetto LIPIGEN


Progetto LIPIGEN - Vecchio portale
E' necessario essere loggati come utente
Lipigen per poter accedere alla pagina

PROject Statin Intolerance SISA


PROSISA – PROject Statin Intolerance SISA
E' necessario essere loggati come utente
PROSISA per poter accedere alla pagina

GILA - Lipoprotein Aferesi


Gruppo Interdisciplinare Lipoprotein Aferesi
(Accesso Gruppo GILA-Lipoprotein Aferesi)

E' necessario essere loggati come utente del Gruppo GILA per poter accedere


Gruppo Interdisciplinare Lipoprotein Aferesi
(Documentazione ad accesso libero)

Pagina informativa per medici e pazienti